[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.237.138.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1987

Prototype Quantitative Assay for Fibrinogen/Fibrin Degradation Products: Clinical Evaluation

Author Affiliations

From the Departments of Pathology and Laboratory Medicine (Drs Sigal, and Cembrowski, and Ms Brown), and Medicine (Dr Shattil), University of Pennsylvania School of Medicine, Philadelphia; and the Biomedical Products Department, E. I. du Pont Corp (Drs Schifreen and Schwartz), Wilmington, Del.

Arch Intern Med. 1987;147(10):1790-1793. doi:10.1001/archinte.1987.00370100104017
Abstract

• A new quantitative assay for fibrinogen/fibrin degradation products (FDPs) was clinically evaluated in 123 tertiary-care patients for whom the standard semiquantitative FDP assay had previously been ordered. On the basis of a comprehensive chart review, 24 patients were categorized as having disseminated intravascular coagulation (DIC), 84 were considered not to have had DIC, ten had fibrinolysis (nine of ten streptokinase induced), and five had a complicated coagulopathy whose exact nature could not be determined. The quantitative and semiquantitative FDP values were significantly correlated. However, the FDP level indicative of DIC was lower by the quantitative assay than by the semiquantitative assay, approximately 18 mg/L vs 40 mg/L, respectively. The advantages of the quantitative over the semiquantitative assay included improved precision and ability to closely monitor changes in the severity of the coagulopathy.

(Arch Intern Med 1987;147:1790-1793)

×